股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 本月底法定/註冊股本總額： HKD 20,000,000 FF301 第 1 頁 共 10 頁 v 1.2.1 截至月份: 2026年3月31日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 今海醫療科技股份有限公司 呈交日期: 2026年4月1日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 (註1) | | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 02225 | 說明 | | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 8,000,000,000 | HKD | | 0.0025 | HKD | | 20,000,000 | | 增加 / 減少 (-) | | | | | | | HKD | | | | 本月底結存 | | | 8, ...

Financial Performance - For the fiscal year ending December 31, 2025, total revenue was SGD 46,276,000, a decrease of 7.8% from SGD 50,241,000 in 2024[4] - Gross profit for the fiscal year was SGD 7,189,000, down 37.5% from SGD 11,477,000 in the previous year[4] - The company reported a pre-tax loss of SGD 17,162,000, slightly improved from a loss of SGD 18,227,000 in 2024[4] - The total comprehensive loss for the year was SGD 16,448,000, compared to SGD 19,111,000 in 2024, indicating a reduction of 13.9%[5] - The company reported a total loss of SGD 17,395,000 for 2025, slightly improved from a loss of SGD 18,255,000 in 2024[12] - The group recorded a loss of SGD 17.4 million in FY2025, compared to a loss of SGD 18.3 million in FY2024, primarily due to decreased gross profit offset by reduced administrative expenses[34] Revenue and Growth - Revenue from customer contracts in China is expected to increase to SGD 29,989,000 in 2025 from SGD 25,927,000 in 2024, reflecting a growth of about 15.8%[11] - Sales from minimally invasive surgical solutions and related medical products increased by SGD 4.037 million to SGD 29.964 million in FY2025[27] - Revenue from minimally invasive surgical solutions and related services increased from SGD 25.9 million in FY2024 to SGD 30.0 million in FY2025, primarily due to growth in the Chinese market[28] - Revenue from labor dispatch and supporting services decreased from SGD 15.1 million in FY2024 to SGD 12.7 million in FY2025, attributed to a downturn in Singapore's dispatch and supporting services[28] Assets and Liabilities - Total assets increased to SGD 88,834,000 in 2025, up from SGD 58,867,000 in 2024, representing a growth of 50.9%[6] - Total liabilities increased to SGD 36,872,000, up from SGD 26,088,000, which is a rise of 41.2%[7] - The company’s equity attributable to owners increased to SGD 51,288,000 from SGD 31,806,000, a growth of 61.2%[6] - As of December 31, 2025, the group's total borrowings and lease liabilities were SGD 14.9 million, a slight increase from SGD 14.5 million in 2024, primarily due to loans from the parent company for operational purposes[44] Cash Flow and Financing - Cash and cash equivalents rose significantly to SGD 35,588,000 from SGD 10,446,000, marking an increase of 240.5%[6] - The group’s cash and cash equivalents as of December 31, 2025, totaled SGD 35.6 million, with 93% held in RMB, 1% in HKD, and 6% in SGD[45] - The company incurred total financing costs of SGD 675,000 in 2025, down from SGD 773,000 in 2024, a reduction of about 12.7%[12] - Financing costs slightly decreased by SGD 0.1 million in FY2025[32] Stock Options and Corporate Governance - The company has adopted a stock option plan approved by shareholders on December 29, 2023, allowing eligible participants to acquire ownership interests in the company[62] - A total of 128,603,750 stock options were granted on January 9, 2024, with an exercise price of HKD 2.54 per share, based on the highest of the closing price on the grant date or the average closing price over the previous five trading days[68] - The stock option plan has a maximum duration of 10 years, with a cap on the total number of shares that can be issued under the plan not exceeding 10% of the issued shares as of the special meeting date[64] - The company has adopted the corporate governance code and complied with all applicable provisions during the year[80] Risk Management - The company has implemented policies to minimize credit risk, including setting credit limits and conducting credit assessments before accepting new customers[57] - Trade receivables are evaluated at each reporting period to ensure adequate impairment losses are recognized, reflecting a significant reduction in credit risk[58] - The company maintains sufficient cash and cash equivalents to manage liquidity risk and reduce cash flow volatility[59] - The company faces fair value risk from financial assets and liabilities measured at fair value on a recurring and non-recurring basis[60] Future Plans and Investments - The group plans to allocate resources towards providing minimally invasive surgical solutions and related services, enhancing R&D capabilities, and expanding distribution networks[23] - The group plans to utilize the proceeds from the August 2025 placement, totaling HKD 161 million, for potential acquisitions in the healthcare sector and R&D expenses, with all funds expected to be used by the end of 2026[43] - The intended use of proceeds includes HKD 69 million for expanding the medical industry business, HKD 15 million for labor dispatch and supporting services, and HKD 15 million for general working capital[42] Employee and Operational Data - The group employed 485 staff members as of December 31, 2025, with total employee costs amounting to SGD 22.5 million for the fiscal year 2025[53] - The audit committee has reviewed the annual audited results and confirmed that the financial statements are prepared in accordance with applicable accounting standards and regulations[82] Miscellaneous - The company has not declared or paid any dividends for the years ending December 31, 2025, and 2024[17] - The group has no significant contingent liabilities as of December 31, 2025[48] - The company has no significant off-balance sheet transactions as of December 31, 2025[52] - The company expresses gratitude to all customers, management, employees, business partners, and shareholders for their continued support[86]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內容概不負責， 對其準確性或完整性亦不發表任何聲明，並明確表示概不就因本公告全部或任何 部份內容而產生或因倚賴該等內容而引致之任何損失承擔任何責任。 董事會會議日期 今海醫療科技股份有限公司（「本公司」）董事（「董事」）會（「董事會」）謹此宣佈， 將於二零二六年三月二十七日舉行董事會會議，旨在考慮及批准（其中包括）本公 司及其附屬公司截至二零二五年十二月三十一日止年度之年度業績之公佈及派發 末期股息（如適用）。 Jinhai Medical Technology Limited 今海醫療科技股份有限公司 （股份代號：2225） （於開曼群島註冊成立的成員有限責任公司） 董事會主席兼執行董事 承董事會命 今海醫療科技股份有限公司 陳國寶 香港，二零二六年三月十三日 於本公告日期，董事會由八名董事組成，其中四名執行董事為陳國寶先生、李斌先 生、王振飛先生及李雲平先生；一名非執行董事為王華生先生；及三名獨立非執行 董事為嚴健軍先生、范一民先生及楊美華女士。 ...

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2026年2月28日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 今海醫療科技股份有限公司 呈交日期: 2026年3月2日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 02225 | 說明 | | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 8,000,000,000 | HKD | | 0.0025 | HKD | | 20,000,000 | | 增加 / 減少 (-) | | | | | | | HKD | | | | 本月底結存 | | | 8,000,000,000 | HKD | | 0.0025 | HKD | | 20,000,000 | 本月底法 ...

Group 1 - The core announcement is that Jin Hai Medical Technology (02225.HK) has signed a capital contribution agreement to increase the registered capital of Jin Hai Biomedical from RMB 5 million to RMB 25 million by February 25, 2026 [1] - Shanghai Jin Hai and Shanghai Anbida Investment will contribute an additional total of RMB 20 million according to their respective equity ratios of 51:49 [1] - As of February 25, 2026, Jin Hai Medical Technology's stock closed at HKD 1.87, down 2.6%, with a trading volume of 3.31 million shares and a turnover of HKD 6.2073 million [1] Group 2 - The company has a market capitalization of HKD 10.157 billion and ranks 8th in the integrated II industry [1] - There has been low attention from investment banks, with no ratings given in the past 90 days [1]

Core Viewpoint - Jin Hai Medical Technology (02225) announced a capital contribution agreement to increase the registered capital of Jin Hai Biomedical from RMB 5 million to RMB 25 million, with additional funding of RMB 20 million from Shanghai Jin Hai and Shanghai Anbida Investment based on their respective shareholding ratios of 51:49 [1] Group 1 - The capital increase aims to enhance the capital strength of Jin Hai Biomedical to support its business development, focusing on the wholesale and distribution of medical devices [1] - The funding amount was determined through fair negotiation between Jin Hai Biomedical and its shareholders, considering the short-term funding needs for business development and investment opportunities [1] - Jin Hai Biomedical will continue to be accounted for as a non-wholly-owned subsidiary in the group's financial statements, regardless of the capital contribution [1]

Group 1 - The core point of the article is that Jin Hai Medical Technology (02225.HK) announced a capital increase for its subsidiary Jin Hai Biomedical, raising its registered capital from RMB 5 million to RMB 25 million through additional investments [1][2] - Jin Hai Biomedical's shareholders agreed to contribute an additional total of RMB 20 million, with Shanghai Jin Hai and Shanghai Anbai Investment investing according to their respective ownership ratios of 51:49 [1] - The announcement also includes the appointment of Li Bin as the executive director and co-chairman of the board [2]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內容概不負責， 對其準確性或完整性亦不發表任何聲明，並明確表示概不就因本公告全部或任何 部份內容而產生或因倚賴該等內容而引致之任何損失承擔任何責任。 Jinhai Medical Technology Limited 今海醫療科技股份有限公司 （於開曼群島註冊成立的成員有限責任公司） （股份代號：2225） 有關向非全資附屬公司出資之關連交易 董事會欣然宣佈，於二零二六年二月二十五日，今海生物醫療、上海今海及上海 安百達投資訂立出資協議，據此，今海生物醫療股東同意將今海生物醫療之繳足 註冊資本由人民幣5,000,000元增至人民幣25,000,000元，由上海今海及上海安百 達投資按彼等各自在今海生物醫療的股權比例51:49額外出資合共繳足註冊資本 人民幣20,000,000元。 據董事作出一切合理查詢後所深知、盡悉及確信，上海安百達投資由李悅女士及 李澤愷先生（分別為執行董事李斌先生之女兒及兒子）控制。 1 出資協議的詳情如下： 日期： 二零二六年二月二十五日（交易時間後） 訂約方： (1) 今海生物醫療 (2) 今海生物醫療股東（即上海今海及上海安 ...

Group 1 - The company announced the appointment of Mr. Li Bin as an executive director, effective from February 3, 2026 [1] - Mr. Li Bin has also been appointed as the co-chairman of the board [1]

Group 1 - The core point of the article is the appointment of Li Bin as an executive director of Jin Hai Medical Technology, effective from February 3, 2026 [1] - Li Bin has also been appointed as the co-chairman of the board [1]